2020 ASCO mCRC Updates Recap: Did We Experience Pseudoprogression With Pembro? Is Toxicity Equally Important as Efficacy? Should We Still Use SCRT as a SoC?
By
Nebraska Oncology Society
FEATURING
George Kim
By
Nebraska Oncology Society
FEATURING
George Kim
Comments 0
Login to view comments.
Click here to Login
